A study revealed that Drinking sugar-sweetened beverages daily may increase the risk of Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic fatty liver disease (NAFLD) is the build up of extra fat in liver cells that is not caused by alcohol. It is normal for the liver to contain some fat. However, if more than 5% - 10% percent of the liver’s weight is fat, then it is called a fatty liver (steatosis).Sugar-sweetened beverages are a major dietary source of fructose, the sugar which is suspected of increasing risk of NAFLD because of how our bodies process it. The study appeared in the Journal of Hepatology.
A new study said that Botulinum toxin, commonly known as Botox could offer an effective new treatment for two forms of neuropathy, pain caused by different types of nerve injury. The study appeared in Anesthesia & Analgesia.
Scientists found the drug was effective in two different strains of mice and three different strains of flu believe the drug could be effective in animals other than mice, including humans. Scientists in Canada developed a new drug that are effective against flu virus.People who die from the flu actually die from respiratory failure, when the lung's tiny blood vessels start leaking fluid into the lung's air sacs. Instead of targeting the virus that causes flu, the new drug can prevent the blood vessels from leaking fluid into the lung's air sacs.
The US FDA has granted approval to Cipla's Lopinavir, Ritonavir (LPV/r) 40mg/ 10 mg oral pellets for paediatric specific treatment of HIV in infants. Cipla was working for many years in collaboration with Diana Gibb, professor of epidemiology, senior programme leader and honorary consultant paediatrician at Medical Research Council Clinical Trials Unit at UCL (University College London) towards development of this novel child-friendly formulation which has been approved by US FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme. This product is a first step in making accessible more modern and appropriately formulated treatment available to the most vulnerable of HIV patients – young children.
The Indian Council on Medical Research (ICMR) and the National Institutes of Health (NIH), US, will soon begin collaborative research on ‘Prevention of Sexually Transmitted Diseases & HIV/AIDS’. The joint research programme will also have thrust on HIV and AIDS-associated co-morbidities. Under this, the focus will be on utilsation of new/enhanced therapeutics for HIV-related co-morbidities such as HCV and their impact on disease outcomes; and enhanced targeted outreach strategies for HCV testing, prevention, and treatment/care engagement; integrated approaches for addressing the complex bio-behavioral factors associated with HCV/HIV. In this regard a joint Indo-US workshop is proposed to be held in September 2015 to encourage investigators for the Indo-US collaborative projects. Under translational research, the focus will be on studies to develop and test innovative HIV prevention strategies in young populations, particularly adolescents; and also on studies to better understand linkages between reproductive health options and HIV infection in men and women.
A master clock in the brain, sends out signals that synchronize the molecular clocks ticking away in almost every cell and tissue of the body. Disruption of the clock linked with a variety of health problems, including diabetes, heart disease, and cancer.
AstraZeneca Pharma India Limited and Dr. Reddy’s Laboratories Ltd. Collaborate to marketing for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and marketed in the Indian market.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
